Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Eye cancer, intraocular melanoma
Stage/Subtype:  recurrent intraocular melanoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-8 of 8 for your search:
Start Over
Calcitriol and Temozolomide in Treating Patients With Stage IV Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 05M1, NCI-2011-00490, NU-0310-093, SPRI-NU-05M1, NCT00301067
Ipilimumab and Palliative Radiation Therapy in Treating Patients with Stage IV Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MEL0005, NCI-2011-03274, 21970, 5136, SU-08242011-8306, NCT01449279
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
Cabozantinib-S-Malate Compared with Temozolomide or Dacarbazine in Treating Patients with Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091201, NCI-2013-00821, CALGB-A091201, NCT01835145
INCB024360 and Vaccine Therapy in Treating Patients with Stage III-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-04, NCI-2013-01605, NCT01961115
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients with Stage IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACCRU RU261206I, NCI-2013-01112, ML28605, NCT01879306, RU261206I, NCT02158520
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 201103308, NCI-2011-00484, 07-0652, 201103308 / 07-0652, NCT00683670
Sotrastaurin Acetate and PI3K Inhibitor BYL719 in Treating Patients with Metastatic Uveal Melanoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAN4901, NCI-2015-00753, CAEB071AUS01T, NCT02273219
Start Over